Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (AWARE-1)

Next Previous
Trial Profile

A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (AWARE-1)

Status: Discontinued
Phase of Trial: Phase 0

Latest Information Update: 28 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Pelareorep (Primary) ; Letrozole; Trastuzumab; Trastuzumab
  • Indications Adenocarcinoma; Early breast cancer; HER2 negative breast cancer; HER2 positive breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use
  • Acronyms AWARE-1
  • Sponsors Oncolytics Biotech

Most Recent Events

  • 24 May 2024 According to an Oncolytics Biotech media release, data from this study will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • 09 Dec 2023 Results applying T cell receptor sequencing of matched tumor tissue and whole blood pre and post-treatment from this study to further explore the effects of pela therapy on TILs, presented at the 46th Annual San Antonio Breast Cancer Symposium
  • 07 Dec 2023 According to an Oncolytics Biotech media release, data from this study were presented at The San Antonio Breast Cancer Symposium (SABCS) 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top